Aegis Downgrades Cynosure, Inc. (CYNO) to Hold

Cynosure, Inc. (NASDAQ:CYNO) was downgraded by research analysts at Aegis from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other research firms have also recently commented on CYNO. TheStreet upgraded Cynosure from a “hold” rating to a “buy” rating in a research note on Wednesday, January 4th. Northland Securities restated an “outperform” rating and set a $60.00 price target on shares of Cynosure in a research note on Thursday, February 16th. Maxim Group cut Cynosure from a “buy” rating to a “hold” rating and set a $66.00 price target on the stock. in a research note on Tuesday, February 14th. Zacks Investment Research upgraded Cynosure from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 21st. Finally, Northcoast Research cut Cynosure from a “buy” rating to a “sell” rating and set a $40.00 price target on the stock. in a research note on Friday, January 6th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $57.88.

Analyst Recommendations for Cynosure (NASDAQ:CYNO)

Shares of Cynosure (NASDAQ:CYNO) traded down 0.038% during mid-day trading on Wednesday, reaching $65.975. The company’s stock had a trading volume of 455,914 shares. The company’s 50-day moving average is $61.02 and its 200-day moving average is $50.59. Cynosure has a 52 week low of $38.93 and a 52 week high of $66.65. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of 109.958 and a beta of 1.65.

Cynosure (NASDAQ:CYNO) last released its quarterly earnings results on Tuesday, February 7th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Cynosure had a return on equity of 6.86% and a net margin of 3.56%. The company had revenue of $122.10 million for the quarter, compared to analysts’ expectations of $119.97 million. During the same period in the prior year, the firm earned $0.42 earnings per share. The firm’s revenue was up 19.2% compared to the same quarter last year. Equities analysts predict that Cynosure will post $1.56 EPS for the current year.

var userip;Your IP Address: document.write(userip);

Several hedge funds have recently bought and sold shares of the company. BlackRock Fund Advisors raised its stake in Cynosure by 7.1% in the third quarter. BlackRock Fund Advisors now owns 1,722,652 shares of the company’s stock worth $87,752,000 after buying an additional 114,653 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Cynosure by 2.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,216,198 shares of the company’s stock worth $55,459,000 after buying an additional 28,394 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Cynosure by 12.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 708,708 shares of the company’s stock worth $36,102,000 after buying an additional 80,700 shares in the last quarter. State Street Corp raised its stake in Cynosure by 4.8% in the fourth quarter. State Street Corp now owns 601,140 shares of the company’s stock worth $27,410,000 after buying an additional 27,748 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in Cynosure by 47.6% in the third quarter. Principal Financial Group Inc. now owns 577,910 shares of the company’s stock worth $29,438,000 after buying an additional 186,455 shares in the last quarter.

About Cynosure

Cynosure, Inc develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women’s health.

5 Day Chart for NASDAQ:CYNO

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.